Article Versions Notes

Chaves OA, Fintelman-Rodrigues N, Wang X, Sacramento CQ, Temerozo JR, Ferreira AC, Mattos M, Pereira-Dutra F, Bozza PT, Castro-Faria-Neto HC, et al. Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones. Viruses. 2022; 14(7):1458. https://doi.org/10.3390/v14071458

Chaves, Otávio Augusto, Natalia Fintelman-Rodrigues, Xuanting Wang, Carolina Q. Sacramento, Jairo R. Temerozo, André C. Ferreira, Mayara Mattos, Filipe Pereira-Dutra, Patrícia T. Bozza, Hugo Caire Castro-Faria-Neto, and et al. 2022. "Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones" Viruses 14, no. 7: 1458. https://doi.org/10.3390/v14071458

Chaves, O. A., Fintelman-Rodrigues, N., Wang, X., Sacramento, C. Q., Temerozo, J. R., Ferreira, A. C., Mattos, M., Pereira-Dutra, F., Bozza, P. T., Castro-Faria-Neto, H. C., Russo, J. J., Ju, J., & Souza, T. M. L. (2022). Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones. Viruses, 14(7), 1458. https://doi.org/10.3390/v14071458